Humana Inc. Q2 2025 Earnings Recap

HUM Q2 2025 August 1, 2025

Get alerts when HUM reports next quarter

Humana reported a strong second quarter, exceeding expectations primarily due to improved individual Medicare Advantage membership and robust performance from CenterWell Pharmacy, leading to an upward revision of its full-year EPS guidance.

Earnings Per Share Beat

$6.27 vs $5.92 est.

+5.9% surprise

Revenue Beat

32388000000 vs 31871526252 est.

+1.6% surprise

Market Reaction

1-Day +0.04%

5-Day +7.85%

30-Day +26.17%

See HUM alongside your other holdings

Add to your portfolio — free

Key Takeaways

Increased full-year EPS outlook raised from approximately $16.25 to $17.
Individual Medicare Advantage membership decline was less than anticipated, aided by retention of previously lost members.
New initiatives announced to simplify the prior authorization process and enhance member experience through a partnership with Epic for integrated health plan information.
Significant progress towards targeted Stars ratings for '27/'28, currently navigating a re-filed legal case regarding Stars litigation.
Ongoing transformation initiatives aimed at optimizing operations, including an early retirement program to streamline costs.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit HUM on AllInvestView.

Next Q3 2025